Broadcast Date:
- Time:
Understanding a drug’s mechanism of action (MOA) can greatly increase the likelihood of successful clinical trials by identifying biomarkers of patient response and providing a rationale for combination therapies. For many drugs and disease states, defining MOA requires unraveling their potential impacts on gene expression. But truly understanding these effects requires a deeper look into chromatin regulation and epigenetic mechanisms.
In this GEN webinar, our expert speaker Dave Lahr, PhD, Senior Director of Bioinformatics at Foghorn Therapeutics, will describe how chromatin mapping assays such as CUT&RUN, ATAC-seq, and bisulfite sequencing enable precise investigation of transcriptional mechanisms in drug discovery. During the webinar, you’ll learn how high-resolution epigenomic tools, including EpiCypher’s CUTANA™ platform, can provide actionable insights into drug-induced changes in transcription factor binding and chromatin structure. You’ll also hear about specific case studies that illustrate how these approaches are used to define MOA and accelerate the development of therapies like targeted protein degraders and enzyme inhibitors.
A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.
Senior Director of Bioinformatics
Foghorn Therapeutics
